Bulletin
Investor Alert

New York Markets Open in:

Oct. 3, 2019, 5:56 p.m. EDT

Immune Checkpoint Inhibitors Market Size and Share to 2024 by Bristol Myer Squibb, AstraZeneca, Merck & Co., Roche / Genentech, Incyte Corporation

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    3M Co. (MMM)
  • X
    Abbott Laboratories (ABT)
  • X
    Allergan PLC (AGN)

or Cancel Already have a watchlist? Log In

Oct 03, 2019 (Reporthive Research via COMTEX) -- Immune Checkpoint Inhibitors Market Analysis, Size, Share, Growth, Trends, and Forecast 2019-2024. This market study answers several questions (like current market status, Size, Share, future market opportunities etc.) for stakeholders, primarily which market segments they should focus upon, during the next few years to prioritize their efforts and investments.

Surge in prevalence of cancer across geographies and increase in awareness of immune checkpoint inhibitors drive the growth of the global immune checkpoint inhibitors market. Furthermore, technological advancements in screening procedure for cancer, increased healthcare expenditures, increase in government initiatives to alleviate cancer, and rise in public awareness are expected to boost the growth of the market. However, high cost associated with research activities is projected to restrain the market growth.

Get the Research Sample Copy @ https://www.reporthive.com/enquiry.php?id=1929243&req_type=smpl

Key Players covered in this report:

Bristol Myer Squibb

AstraZeneca

Merck & Co.

Roche / Genentech

Incyte Corporation and more

Immune checkpoint inhibitor is a type of drug used in immunotherapy. Although traditional chemotherapeutic drugs remain the first-line option for treatment of most cancer types, targeted immune therapies are emerging as standard treatments for advanced-stage cancers. These drugs target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system.

Asia-Pacific presents lucrative opportunities for the key players operating in the immune checkpoint inhibitors market, owing to large population base, growth in awareness about advanced immune therapy, surge in incidence of cancer, and improvement of healthcare infrastructure. China, Japan, and India have high prevalence of cancer, which is expected to drive the demand for immune check point inhibitors in near future. However, healthcare insurance providers do not cover the entire expenses for the treatment of cancer. This factor is estimated to hamper the market growth in the Asia-Pacific region.

Key Product Type

PD-1/PD-L1

CTLA-4

Market by Application

Lung Cancer

Colorectal Cancer

Breast Cancer

Prostate Cancer

Melanoma

Blood Cancer

Others

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a 5-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Get the Full Research Report @ https://www.reporthive.com/checkout?currency=single-user-licence&reportid=1929243

Table of Contents

1 Executive Summary Market Attractiveness Analysis

1.1 Global Immune Checkpoint Inhibitors Market, by Product Type

1.2 Global Immune Checkpoint Inhibitors Market, by End User

1.3 Global Immune Checkpoint Inhibitors Market, by Region

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.3 Market Structure

2.4 Key Buying Criteria

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.